Drug Discovery

The transition from siloed research environments to fully integrated, autonomous ecosystems represents a fundamental shift in how scientific discovery is conducted at scale. In the current landscape, the complexity of biopharmaceutical research requires more than just faster instrumentation; it

The reliance on non-human biological models has long been a bottleneck in the pharmaceutical pipeline, leading to costly failures when results from mice or monkeys fail to replicate in clinical settings. However, the recent unveiling of the Pakistan Genome Resource provides a massive leap forward

The scientific community has long searched for a way to reverse the cellular decay associated with chronic organ failure, yet recent breakthroughs suggest that a medication originally designed to repair cardiac tissue may hold the key to regenerating damaged kidneys. This innovative therapeutic

The transition from traditional trial-and-error chemical assays to high-precision computational forecasting has effectively rewritten the blueprint for modern therapeutic development across the global pharmaceutical industry. This evolution is particularly evident in the fight against Idiopathic

Ivan Kairatov is a distinguished biopharma expert with a deep background in research and development, focusing on the intersection of technology and patient-centric innovation. In this discussion, we explore the implications of the U.S. FDA’s recent acceptance of Gilead’s supplemental New Drug

The traditional reliance on non-selective systemic chemotherapy for treating advanced gynecological malignancies is rapidly fading as clinicians embrace the precision of antibody–drug conjugates. For decades, the standard approach to ovarian, cervical, and endometrial cancers involved cytotoxic